 Mark Gerich
Concepts (242)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Crohn Disease | 9 | 2022 | 260 | 1.680 |
Why?
| | Inflammatory Bowel Diseases | 11 | 2026 | 365 | 1.510 |
Why?
| | Medical Marijuana | 4 | 2017 | 123 | 1.280 |
Why?
| | Gastrointestinal Diseases | 3 | 2016 | 216 | 1.160 |
Why?
| | Immunosuppressive Agents | 5 | 2020 | 846 | 1.150 |
Why?
| | Colitis | 11 | 2025 | 280 | 1.130 |
Why?
| | Thalidomide | 2 | 2015 | 43 | 0.870 |
Why?
| | Colitis, Ulcerative | 6 | 2024 | 147 | 0.840 |
Why?
| | Intestinal Mucosa | 9 | 2025 | 676 | 0.730 |
Why?
| | Patient Acceptance of Health Care | 4 | 2026 | 885 | 0.390 |
Why?
| | Drug Resistance | 1 | 2013 | 153 | 0.370 |
Why?
| | Salvage Therapy | 1 | 2013 | 162 | 0.360 |
Why?
| | Intestines | 3 | 2021 | 358 | 0.360 |
Why?
| | Tacrolimus | 1 | 2013 | 196 | 0.360 |
Why?
| | Colonic Pouches | 1 | 2011 | 14 | 0.340 |
Why?
| | Proctocolectomy, Restorative | 1 | 2011 | 23 | 0.340 |
Why?
| | Intestinal Neoplasms | 1 | 2011 | 30 | 0.340 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2022 | 1217 | 0.330 |
Why?
| | Mercaptopurine | 1 | 2010 | 15 | 0.320 |
Why?
| | Spondylitis, Ankylosing | 2 | 2021 | 43 | 0.320 |
Why?
| | Antiporters | 2 | 2021 | 22 | 0.320 |
Why?
| | Allopurinol | 1 | 2010 | 69 | 0.320 |
Why?
| | Colon | 3 | 2025 | 304 | 0.310 |
Why?
| | Algorithms | 4 | 2026 | 1837 | 0.310 |
Why?
| | Acidosis | 2 | 2021 | 105 | 0.300 |
Why?
| | Precision Medicine | 1 | 2013 | 457 | 0.300 |
Why?
| | Enzyme Inhibitors | 2 | 2010 | 824 | 0.300 |
Why?
| | Spondylarthritis | 2 | 2021 | 50 | 0.290 |
Why?
| | Dextran Sulfate | 6 | 2024 | 92 | 0.290 |
Why?
| | Gastrointestinal Microbiome | 3 | 2022 | 771 | 0.270 |
Why?
| | Tryptophan | 2 | 2021 | 181 | 0.260 |
Why?
| | Ileitis | 2 | 2021 | 33 | 0.260 |
Why?
| | Neutrophils | 3 | 2024 | 1134 | 0.260 |
Why?
| | Disease Models, Animal | 9 | 2025 | 4557 | 0.250 |
Why?
| | Antibodies, Monoclonal | 1 | 2013 | 1519 | 0.230 |
Why?
| | Heme Oxygenase-1 | 1 | 2025 | 74 | 0.230 |
Why?
| | Endocannabinoids | 2 | 2017 | 57 | 0.220 |
Why?
| | MicroRNAs | 2 | 2024 | 701 | 0.220 |
Why?
| | Legislation, Drug | 2 | 2016 | 73 | 0.210 |
Why?
| | Humans | 39 | 2026 | 144759 | 0.210 |
Why?
| | Tight Junction Proteins | 1 | 2024 | 15 | 0.210 |
Why?
| | United States Food and Drug Administration | 2 | 2016 | 203 | 0.210 |
Why?
| | Adenocarcinoma | 1 | 2011 | 928 | 0.200 |
Why?
| | Th1 Cells | 1 | 2024 | 139 | 0.200 |
Why?
| | Peroxidase | 1 | 2024 | 168 | 0.200 |
Why?
| | Carcinogenesis | 1 | 2025 | 229 | 0.200 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2024 | 91 | 0.200 |
Why?
| | Colonic Neoplasms | 1 | 2025 | 259 | 0.200 |
Why?
| | Iron | 1 | 2025 | 359 | 0.190 |
Why?
| | Colonic Polyps | 1 | 2024 | 85 | 0.190 |
Why?
| | Drug Monitoring | 1 | 2026 | 395 | 0.180 |
Why?
| | Microbiota | 2 | 2022 | 781 | 0.180 |
Why?
| | Inflammation | 5 | 2024 | 2878 | 0.170 |
Why?
| | Colonoscopy | 1 | 2024 | 261 | 0.170 |
Why?
| | Infliximab | 3 | 2020 | 108 | 0.170 |
Why?
| | Metabolomics | 3 | 2022 | 727 | 0.160 |
Why?
| | Ustekinumab | 1 | 2020 | 17 | 0.160 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2021 | 145 | 0.160 |
Why?
| | Plasma Membrane Neurotransmitter Transport Proteins | 1 | 2020 | 6 | 0.160 |
Why?
| | Male | 19 | 2026 | 72315 | 0.160 |
Why?
| | Mice, Knockout | 6 | 2025 | 3121 | 0.160 |
Why?
| | Mucin 5AC | 1 | 2020 | 70 | 0.160 |
Why?
| | Killer Cells, Natural | 1 | 2023 | 467 | 0.150 |
Why?
| | Gastrointestinal Agents | 1 | 2020 | 66 | 0.150 |
Why?
| | Quality Assurance, Health Care | 1 | 2021 | 340 | 0.150 |
Why?
| | Artificial Intelligence | 1 | 2024 | 365 | 0.150 |
Why?
| | Metagenomics | 1 | 2021 | 181 | 0.150 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1985 | 0.150 |
Why?
| | Adult | 14 | 2026 | 40449 | 0.150 |
Why?
| | Membrane Transport Proteins | 1 | 2020 | 154 | 0.150 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2021 | 233 | 0.140 |
Why?
| | Receptors, Cannabinoid | 2 | 2017 | 14 | 0.140 |
Why?
| | Intraepithelial Lymphocytes | 1 | 2018 | 16 | 0.140 |
Why?
| | Receptors, Interleukin-10 | 1 | 2018 | 7 | 0.140 |
Why?
| | Middle Aged | 11 | 2026 | 35875 | 0.140 |
Why?
| | Health Care Costs | 1 | 2021 | 427 | 0.140 |
Why?
| | Mice | 12 | 2025 | 18339 | 0.140 |
Why?
| | Hospitalization | 3 | 2026 | 2433 | 0.130 |
Why?
| | Microfluidic Analytical Techniques | 1 | 2018 | 81 | 0.130 |
Why?
| | Thrombophilia | 1 | 2018 | 88 | 0.130 |
Why?
| | Interleukin-10 Receptor alpha Subunit | 1 | 2017 | 5 | 0.130 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2023 | 917 | 0.130 |
Why?
| | Thrombelastography | 1 | 2018 | 178 | 0.130 |
Why?
| | Ambulatory Care | 1 | 2021 | 600 | 0.130 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 55 | 0.120 |
Why?
| | Mice, Inbred C57BL | 6 | 2025 | 5992 | 0.120 |
Why?
| | Quality of Health Care | 1 | 2021 | 691 | 0.120 |
Why?
| | Fecal Microbiota Transplantation | 1 | 2016 | 26 | 0.120 |
Why?
| | Nerve Tissue Proteins | 1 | 2020 | 592 | 0.120 |
Why?
| | Female | 14 | 2026 | 78271 | 0.120 |
Why?
| | Myeloid Cells | 1 | 2017 | 148 | 0.120 |
Why?
| | Drug and Narcotic Control | 1 | 2016 | 24 | 0.120 |
Why?
| | Cannabinoids | 2 | 2017 | 182 | 0.120 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2017 | 169 | 0.120 |
Why?
| | Inflammasomes | 1 | 2017 | 146 | 0.120 |
Why?
| | Clostridium Infections | 1 | 2016 | 74 | 0.110 |
Why?
| | Retrospective Studies | 6 | 2026 | 17066 | 0.110 |
Why?
| | Delivery of Health Care | 1 | 2021 | 947 | 0.110 |
Why?
| | Nausea | 1 | 2014 | 111 | 0.100 |
Why?
| | Animals | 13 | 2025 | 38058 | 0.100 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 985 | 0.100 |
Why?
| | Steroids | 1 | 2014 | 160 | 0.100 |
Why?
| | Indoles | 1 | 2018 | 501 | 0.100 |
Why?
| | Vomiting | 1 | 2014 | 130 | 0.100 |
Why?
| | Case-Control Studies | 5 | 2021 | 3604 | 0.100 |
Why?
| | Anti-Inflammatory Agents | 1 | 2017 | 474 | 0.100 |
Why?
| | Attitude to Health | 1 | 2016 | 436 | 0.090 |
Why?
| | alpha 1-Antitrypsin | 1 | 2013 | 102 | 0.090 |
Why?
| | United States | 4 | 2021 | 15966 | 0.090 |
Why?
| | Tight Junctions | 2 | 2024 | 81 | 0.090 |
Why?
| | Prospective Studies | 4 | 2024 | 7990 | 0.090 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2011 | 16 | 0.090 |
Why?
| | Feces | 2 | 2026 | 513 | 0.080 |
Why?
| | Guanine Nucleotides | 1 | 2010 | 12 | 0.080 |
Why?
| | Administration, Oral | 1 | 2013 | 847 | 0.080 |
Why?
| | Thionucleotides | 1 | 2010 | 35 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 2027 | 0.080 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 338 | 0.080 |
Why?
| | Biological Products | 2 | 2026 | 252 | 0.080 |
Why?
| | Methyltransferases | 1 | 2010 | 74 | 0.080 |
Why?
| | Chronic Disease | 3 | 2022 | 1813 | 0.070 |
Why?
| | Follow-Up Studies | 2 | 2021 | 5408 | 0.070 |
Why?
| | Genotype | 1 | 2013 | 1833 | 0.070 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 779 | 0.070 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2008 | 27 | 0.070 |
Why?
| | Hypoxia-Inducible Factor 1 | 1 | 2008 | 69 | 0.070 |
Why?
| | Disease Susceptibility | 2 | 2021 | 348 | 0.060 |
Why?
| | Cost-Benefit Analysis | 2 | 2020 | 634 | 0.060 |
Why?
| | Prognosis | 2 | 2013 | 4282 | 0.060 |
Why?
| | Epithelial Cells | 2 | 2025 | 1125 | 0.060 |
Why?
| | Leukocyte L1 Antigen Complex | 1 | 2026 | 40 | 0.060 |
Why?
| | Lipid Peroxidation | 1 | 2025 | 160 | 0.060 |
Why?
| | Heme | 1 | 2025 | 89 | 0.060 |
Why?
| | Homeostasis | 2 | 2020 | 640 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 2363 | 0.060 |
Why?
| | Immunity, Innate | 1 | 2011 | 846 | 0.050 |
Why?
| | Treatment Outcome | 2 | 2025 | 11679 | 0.050 |
Why?
| | Young Adult | 2 | 2013 | 14105 | 0.050 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2025 | 133 | 0.050 |
Why?
| | Halogenation | 1 | 2024 | 23 | 0.050 |
Why?
| | Remission Induction | 1 | 2025 | 307 | 0.050 |
Why?
| | T-Box Domain Proteins | 1 | 2024 | 106 | 0.050 |
Why?
| | Canada | 1 | 2025 | 428 | 0.050 |
Why?
| | C-Reactive Protein | 1 | 2026 | 416 | 0.050 |
Why?
| | Cell Line | 2 | 2020 | 2882 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2025 | 405 | 0.050 |
Why?
| | Prevalence | 1 | 2010 | 2834 | 0.050 |
Why?
| | Immunoglobulins | 1 | 2023 | 160 | 0.050 |
Why?
| | Receptors, KIR | 1 | 2023 | 110 | 0.050 |
Why?
| | Phosphorylation | 2 | 2021 | 1732 | 0.050 |
Why?
| | Thymus Gland | 1 | 2023 | 311 | 0.050 |
Why?
| | Adenoma | 1 | 2024 | 218 | 0.040 |
Why?
| | Phenotype | 1 | 2010 | 3162 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 331 | 0.040 |
Why?
| | Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2021 | 13 | 0.040 |
Why?
| | Dual Specificity Phosphatase 1 | 1 | 2021 | 23 | 0.040 |
Why?
| | Cost Savings | 1 | 2021 | 86 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 673 | 0.040 |
Why?
| | Granzymes | 1 | 2021 | 49 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2025 | 488 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2021 | 196 | 0.040 |
Why?
| | Ileum | 1 | 2021 | 111 | 0.040 |
Why?
| | Azathioprine | 1 | 2020 | 49 | 0.040 |
Why?
| | Protective Factors | 1 | 2020 | 99 | 0.040 |
Why?
| | Adalimumab | 1 | 2020 | 55 | 0.040 |
Why?
| | Leukocyte Disorders | 1 | 2019 | 9 | 0.040 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 121 | 0.040 |
Why?
| | Sodium Dodecyl Sulfate | 1 | 2019 | 26 | 0.040 |
Why?
| | Markov Chains | 1 | 2020 | 129 | 0.040 |
Why?
| | Models, Economic | 1 | 2020 | 62 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2021 | 187 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2021 | 292 | 0.040 |
Why?
| | Gene Expression Regulation | 2 | 2021 | 2608 | 0.040 |
Why?
| | Transendothelial and Transepithelial Migration | 1 | 2019 | 30 | 0.040 |
Why?
| | Colectomy | 1 | 2020 | 107 | 0.040 |
Why?
| | Immune System Diseases | 1 | 2019 | 39 | 0.040 |
Why?
| | Neutrophil Activation | 1 | 2019 | 85 | 0.040 |
Why?
| | Organoids | 1 | 2021 | 141 | 0.040 |
Why?
| | Dysbiosis | 1 | 2021 | 187 | 0.040 |
Why?
| | Membrane Proteins | 1 | 2025 | 1166 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2020 | 336 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2025 | 1339 | 0.040 |
Why?
| | Surgical Wound Infection | 1 | 2022 | 316 | 0.040 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2021 | 327 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 442 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2020 | 558 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2024 | 1129 | 0.030 |
Why?
| | Adenosine | 1 | 2019 | 255 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2010 | 8265 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 1047 | 0.030 |
Why?
| | Receptors, CCR2 | 1 | 2017 | 39 | 0.030 |
Why?
| | Aged | 2 | 2024 | 25913 | 0.030 |
Why?
| | Up-Regulation | 1 | 2019 | 851 | 0.030 |
Why?
| | Biopsy | 1 | 2020 | 1075 | 0.030 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2017 | 60 | 0.030 |
Why?
| | Child | 2 | 2022 | 22633 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1886 | 0.030 |
Why?
| | Kynurenine | 1 | 2017 | 114 | 0.030 |
Why?
| | Colorectal Neoplasms | 1 | 2024 | 845 | 0.030 |
Why?
| | Computational Biology | 1 | 2021 | 680 | 0.030 |
Why?
| | Hematopoiesis | 1 | 2017 | 194 | 0.030 |
Why?
| | Clinical Competence | 1 | 2024 | 1244 | 0.030 |
Why?
| | Adaptation, Physiological | 1 | 2019 | 570 | 0.030 |
Why?
| | Signal Transduction | 2 | 2021 | 5226 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2017 | 395 | 0.030 |
Why?
| | Antibodies | 1 | 2017 | 401 | 0.030 |
Why?
| | Interleukin-10 | 1 | 2017 | 309 | 0.030 |
Why?
| | Child, Preschool | 1 | 2010 | 11787 | 0.030 |
Why?
| | Incidence | 1 | 2021 | 2879 | 0.030 |
Why?
| | Monocytes | 1 | 2017 | 538 | 0.030 |
Why?
| | Energy Metabolism | 1 | 2020 | 935 | 0.030 |
Why?
| | Wound Healing | 1 | 2017 | 351 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1782 | 0.030 |
Why?
| | Bacteria | 1 | 2020 | 889 | 0.020 |
Why?
| | Base Sequence | 1 | 2017 | 2190 | 0.020 |
Why?
| | Mitochondria | 1 | 2020 | 984 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2017 | 784 | 0.020 |
Why?
| | Cell Membrane Permeability | 1 | 2013 | 85 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1982 | 0.020 |
Why?
| | Quality of Life | 1 | 2025 | 3185 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 1257 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2019 | 4154 | 0.020 |
Why?
| | Cohort Studies | 1 | 2022 | 5960 | 0.020 |
Why?
| | Granulocytes | 1 | 2011 | 80 | 0.020 |
Why?
| | Nanoparticles | 1 | 2017 | 519 | 0.020 |
Why?
| | Time Factors | 1 | 2021 | 7173 | 0.020 |
Why?
| | Adolescent | 1 | 2010 | 22428 | 0.020 |
Why?
| | Acute Disease | 1 | 2013 | 1030 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2011 | 161 | 0.020 |
Why?
| | Pancreatic Neoplasms | 1 | 2018 | 919 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2013 | 1173 | 0.020 |
Why?
| | STAT3 Transcription Factor | 1 | 2011 | 207 | 0.020 |
Why?
| | ROC Curve | 1 | 2011 | 614 | 0.020 |
Why?
| | Down-Regulation | 1 | 2011 | 627 | 0.020 |
Why?
| | HeLa Cells | 1 | 2008 | 650 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 2115 | 0.010 |
Why?
| | Cytokines | 1 | 2013 | 2061 | 0.010 |
Why?
| | Cell Culture Techniques | 1 | 2008 | 375 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2925 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2011 | 2832 | 0.010 |
Why?
| | Colorado | 1 | 2011 | 4564 | 0.010 |
Why?
| | Biomarkers | 1 | 2011 | 4271 | 0.010 |
Why?
|
|
Gerich's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|